Answers are grounded in this paper and cite their sources.
SARS-CoV-2 continues to evolve, generating successive variants with enhanced resistance to antibody-mediated neutralization. However, many existing monoclonal antibodies (mAbs) were derived from ancestral or early Omicron strains and have lost activity against recent variants, limiting their ability to resolve the antigenic effects of mutations arising in emerging lineages. Here, we generated a mAb panel by immunizing naive, unimprinted VelocImmune mice with the KP.3.1.1 spike, and isolated and characterized 11 human neutralizing antibodies targeting diverse epitopes of evolved variants. We then integrated these antibodies with characterized mAbs to establish a toolbox for profiling antigenic evolution among emerging variants. Application of this panel to emerging variants provided mechanistic insight into recent antigenic evolution, highlighting the potential role of altered receptor-binding domain conformation. Our data also revealed clear differences in antibody-evasion profiles between JN.1-derived lineages and BA.3.2 lineages. Together, our findings establish an updated mAb panel for monitoring antigenic evolution of JN.1 subvariants.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: